Belgium-based Argenx NV has made its debut on the Nasdaq over-the-counter market in the US, capping what has been nearly a decade of successful antibody discovery and development. On 17 May, it announced the pricing of an initial public offering (IPO) of its shares that was set to yield $100 million.
